SMC2 and pancreatic neoplasm: At day 53, the volumes of the pancreatic tumor were 1.4 ± 1.2 cm3 in the controls, 0.9 ± 1.2 cm3 in the CAPE-treated group, and 0.6 ± 0.2 cm3 in the gemcitabine-treated group (Figure 6(a)).